India is one of the developing countries. A substantial proportion of population of this country is largely exposed to the drug market whose purchasing power is extremely low. Around 42% population of this country lives under the National poverty line ($1.25 per day). Vital issue concerning them is to access the health care facility at an affordable cost. Medicine is a part of health care cost and it costs to around 70% to 80% of total cost. Thus, cost of medicine is a governing factor of health care system especially when it comes to price control of health care facilities. To bring down the cost of health care facilities, government spends money for health care facilities. A comparative expenditure made by state government is depicted in this article. NPPA (National Pharmaceutical Pricing Authority) is the Indian pharmaceutical pricing regulating authority and it achieves its objectives by implementing the DPCO (Drug Pricing control order). In spite of existence of the DPCO, drastic price variation is observed between the products of same API (Active Pharmaceutical Ingredient) and several factors are responsible for the same. To overcome the stated problem and monopolistic trade practice by patent holder/brand manufacturer, TRIPS (Trade Related Intellectual Properties Rights) provides Compulsory Licenses which has its unique role to play in affordability of medicines. Essential medicine is a basic requirement of health care system to serve their customers and hence an effective and overt price control on drugs is the need of present. This study will thus try to justify the need to bring NLEM (National List of Essential Medicine) under DPCO.
The price of drugs that were neither under price control nor under the EDL grew by 137%. Once these essential medicines are brought under Drug Price Control Order (DPCO), it cannot be sold at a price higher than that fixed by the government. This will put a cap on the maximum price at which essential drugs, like some commonly used anti-AIDS and anti-cancer drugs, besides a horde of painkillers, anti-TB drugs, sedatives, lipid lowering agents and steroids, can be sold in the country. Lack of access to much needed medicines may be due to high costs of the drugs, low purchasing power or nonavailability. Each of these elements which result in poor access should be analysed for better access of the drugs. 
Expenses on Medicines

NPPA and DPCO
NPPA is an organization of the Government of The organization is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.
It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.
Functions of NPPA 5
To implement and enforce the provisions of the Drugs (Prices Control) Order in accordance with the powers delegated to it.
To deal with all legal matters arising out of the decisions of the Authority.
To monitor the availability of drugs, identify shortages, if any, and to take remedial steps.
To collect/maintain data on production, exports and imports, market share of individual companies, profitability of companies etc, for bulk drugs and formulations.
To undertake and/or sponsor relevant studies in respect of pricing of drugs/ pharmaceuticals.
To recruit/appoint the officers and other staff members of the Authority, as per rules and procedures laid down by the Government.
To render advice to the Central Government on changes/revisions in the drug policy.
To render assistance to the Central As shown in Figure 1 DPCO provides power to fix ceiling price to fix formulation prices, to fix ceiling price, to recover dues, to recover overcharged amount, to entry, search and seizure and to review, to issue guidelines and directions, to exempt.
The Pricing of Bulk Drugs
The 76 Step 2: Collection of data:
Data is collected by issuing questionnaire/Form I of DPCO, 1995/costaudit report etc. and verification by plant visits, if required.
Step 3: Preparation of actual cost statement:
Actual cost for the year for which data is submitted is prepared based on data submitted / collected & verified during plant visit.
Step 4 Step 5: Preparation of estimated cost Step 6: Calculation of fair price of bulk drug Step 7: Fixation of maximum sale price of the drug When the number of manufacturers of the said drug is more than one, the maximum sale price is fixed at 2/3rd cut off level or weighted average price, depending upon the situation.
Step 8: Notification of bulk drug price in official gazette
After calculating the maximum sales price of the bulk drug, it is notified in the official Gazette.
CONCLUSION:
In its present form, DPCO is ineffective as it is inadequate in its coverage and do not serve its 
